JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $7 price target.
June 28, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Elevation Oncology and maintained a $7 price target, indicating continued confidence in the company's performance.
The reiteration of a Market Outperform rating and the maintenance of a $7 price target by JMP Securities suggests strong confidence in Elevation Oncology's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100